comparemela.com

Latest Breaking News On - Medical treatments procedures - Page 10 : comparemela.com

NKGen Biotech Gets Clearance to Begin Alzheimer s Disease Treatment Trials in Canada

By Adriano Marchese NKGen Biotech said Wednesday it has received regulatory clearance to begin trials for its cell therapy to treat patients with moderate.

United statesAdriano marcheseHealth canadaArticle normalBiotechnology servicesFinancial investment servicesHealthcare life sciencesFinancial servicesInvesting securitiesNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingPolitical general newsMedical conditions

Cytokinetics stock rockets toward a 19-year high after positive trial data on heart disease treatment

Cytokinetics' stock rocketed Wednesday, after the cardiovascular-biopharmaceutical company announced positive results from a Phase 3 trial of aficamten, a.

Cytokinetics incShares biotechnologyArticle normalHealthcare life sciencesAnalyst comment recommendationNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingCardiovascular conditionsPolitical general newsMedical conditionsScience technologyMedical treatments proceduresEquity markets

Guess What, Buddy? I m a Match How Work Friends Saved One Banker s Life

Bill Carroll told his colleagues at UBS that he was sick. They raced to find him a kidney.

Bill carrollPhoto commissionWsjfinance wsCommercial bankingBanking creditFinancial servicesInternational banksNorth americaUnited statesNortheast usNew jerseyPolitical general newsOrgan tissue transplantsMedical treatments proceduresWsj pro comUbs group

Karuna Therapeutics stock rockets into record territory after Bristol Myers $14 billion buyout deal

Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought.

Christopher boernerBristol myerBristol myersKaruna therapeutics incDrug administrationBristol myers squibb coKaruna therapeuticsBristol myers squibbWall streetBristol myers chief executive christopherArticle normalBiotechnology servicesHealthcare life sciencesRegulation government policyFinancial performanceShare price movement disruptions

Bristol Myers to Buy Karuna Therapeutics for $14 Billion

Cash deal would help Bristol establish a beachhead in neuroscience drugs, including a schizophrenia treatment up for approval

Bristol myers squibbKaruna therapeuticsBiotechnology servicesCancer drugsHealthcare life sciencesSpecialized drugs medicationsUnited kingdomWestern europeRegulation government policyOwnership changesAcquisitions mergers shareholdingsNew products servicesAcquisitions mergersCorporate actionsProduct service approvalsCorporate industrial news

vimarsana © 2020. All Rights Reserved.